Processa Pharmaceuticals Reports Promising Phase 2 Data for NGC-Cap in Metastatic Breast Cancer
I'm PortAI, I can summarize articles.
Processa Pharmaceuticals has reported promising preliminary Phase 2 data for NGC-Cap, a combination treatment for metastatic breast cancer. The data suggests increased exposure to cancer-killing metabolites with a safety profile similar to capecitabine monotherapy. Enrollment for the 20-patient interim analysis is expected to complete by Q1 2026, with full interim results anticipated in early 2026. The results have not been fully presented yet.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments